The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3

Murali Janakiram, Urvi A. Shah, Weifeng Liu, Aimin Zhao, Mark P. Schoenberg, Xingxing Zang

Research output: Contribution to journalReview article

41 Citations (Scopus)

Abstract

The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules (B7-H3 [CD276], B7x [B7-H4/B7S1], and HHLA2 [B7H7/B7-H5]/TMIGD2 [IGPR-1/CD28H]) of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure, and function of B7-H3, B7x, HHLA2, and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)26-39
Number of pages14
JournalImmunological Reviews
Volume276
Issue number1
DOIs
StatePublished - Mar 1 2017

Fingerprint

Autoimmune Diseases
B7 Antigens
Neoplasms
Transplantation
Monoclonal Antibodies
Ligands
T-Lymphocytes
Infection
Proteins
Therapeutics

Keywords

  • B7-H3
  • B7x
  • HHLA2
  • immune checkpoint
  • immunotherapy
  • TMIGD2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The third group of the B7-CD28 immune checkpoint family : HHLA2, TMIGD2, B7x, and B7-H3. / Janakiram, Murali; Shah, Urvi A.; Liu, Weifeng; Zhao, Aimin; Schoenberg, Mark P.; Zang, Xingxing.

In: Immunological Reviews, Vol. 276, No. 1, 01.03.2017, p. 26-39.

Research output: Contribution to journalReview article

Janakiram, Murali ; Shah, Urvi A. ; Liu, Weifeng ; Zhao, Aimin ; Schoenberg, Mark P. ; Zang, Xingxing. / The third group of the B7-CD28 immune checkpoint family : HHLA2, TMIGD2, B7x, and B7-H3. In: Immunological Reviews. 2017 ; Vol. 276, No. 1. pp. 26-39.
@article{b981da2803a84726bc86f772939788fb,
title = "The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3",
abstract = "The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules (B7-H3 [CD276], B7x [B7-H4/B7S1], and HHLA2 [B7H7/B7-H5]/TMIGD2 [IGPR-1/CD28H]) of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure, and function of B7-H3, B7x, HHLA2, and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.",
keywords = "B7-H3, B7x, HHLA2, immune checkpoint, immunotherapy, TMIGD2",
author = "Murali Janakiram and Shah, {Urvi A.} and Weifeng Liu and Aimin Zhao and Schoenberg, {Mark P.} and Xingxing Zang",
year = "2017",
month = "3",
day = "1",
doi = "10.1111/imr.12521",
language = "English (US)",
volume = "276",
pages = "26--39",
journal = "Immunological Reviews",
issn = "0105-2896",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - The third group of the B7-CD28 immune checkpoint family

T2 - HHLA2, TMIGD2, B7x, and B7-H3

AU - Janakiram, Murali

AU - Shah, Urvi A.

AU - Liu, Weifeng

AU - Zhao, Aimin

AU - Schoenberg, Mark P.

AU - Zang, Xingxing

PY - 2017/3/1

Y1 - 2017/3/1

N2 - The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules (B7-H3 [CD276], B7x [B7-H4/B7S1], and HHLA2 [B7H7/B7-H5]/TMIGD2 [IGPR-1/CD28H]) of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure, and function of B7-H3, B7x, HHLA2, and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.

AB - The B7-CD28 family of ligands and receptors play important roles in T-cell co-stimulation and co-inhibition. Phylogenetically they can be divided into three groups. The recent discovery of the new molecules (B7-H3 [CD276], B7x [B7-H4/B7S1], and HHLA2 [B7H7/B7-H5]/TMIGD2 [IGPR-1/CD28H]) of the group III has expanded therapeutic possibilities for the treatment of human diseases. In this review, we describe the discovery, structure, and function of B7-H3, B7x, HHLA2, and TMIGD2 in immune regulation. We also discuss their roles in important pathological states such as cancers, autoimmune diseases, transplantation, and infection. Various immunotherapeutical approaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to inhibit or potentiate these molecules and pathways in cancers and autoimmune diseases.

KW - B7-H3

KW - B7x

KW - HHLA2

KW - immune checkpoint

KW - immunotherapy

KW - TMIGD2

UR - http://www.scopus.com/inward/record.url?scp=85014391455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014391455&partnerID=8YFLogxK

U2 - 10.1111/imr.12521

DO - 10.1111/imr.12521

M3 - Review article

C2 - 28258693

AN - SCOPUS:85014391455

VL - 276

SP - 26

EP - 39

JO - Immunological Reviews

JF - Immunological Reviews

SN - 0105-2896

IS - 1

ER -